Phase I lead-in and subsequent randomized trial assessing safety and modulation of regulatory T cell numbers following a maximally tolerated dose doxorubicin and metronomic dose cyclophosphamide combination chemotherapy protocol in tumour-bearing dogs-Reference-Cited by-同舟云学术

Phase I lead-in and subsequent randomized trial assessing safety and modulation of regulatory T cell numbers following a maximally tolerated dose doxorubicin and metronomic dose cyclophosphamide combination chemotherapy protocol in tumour-bearing dogs

Published:2015-11-01 Issue:2 Volume:15 Page:421-430
ISSN:1476-5810
Container-title:Veterinary and Comparative Oncology
language:en
Short-container-title:Vet Comp Oncol

Author:

Rasmussen R. M.¹,Kurzman I. D.¹,Biller B. J.²,Guth A.²,Vail D. M.¹³

Affiliation:

1. Department of Medical Sciences, School of Veterinary Medicine; University of Wisconsin-Madison; Madison WI USA

2. Flint Animal Cancer Center; Colorado State University; Fort Collins CO USA

3. The Carbone Cancer Center; University of Wisconsin-Madison; Madison WI USA

Funder

Barbara A. Suran Comparative Oncology Research endowment

Animal Cancer Treatment Program at the University of Wisconsin School of Veterinary Medicine

Publisher

Wiley

Subject

General Veterinary

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/vco.12179/fullpdf

Reference24 articles.

1. The anti-angiogenic basis of metronomic chemotherapy;Kerbel;Nature Reviews Cancer,2004

2. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy;Shaked;Cancer Research,2005

3. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells;Bertolini;Cancer Research,2003

4. A multitargeted, metronomic, and maximum-tolerated dose “chemo-switch” regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer;Pietras;Journal of Clinical Oncology,2005

5. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models;Daenen;Molecular Cancer Therapeutics,2009

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metronomic chemotherapy: bridging theory to clinical application in canine and feline oncology;Frontiers in Veterinary Science;2024-06-06

2. Management of the Immunosuppressed Patient;Infection Control in Small Animal Clinical Practice;2023-05-02

3. Complete recovery of a cyclophosphamide overdose after vincristine administration in a dog;Veterinary Record Case Reports;2023-03-13

4. Metronomic Chemotherapy for Palliative Treatment of Malignant Oral Tumors in Dogs;Frontiers in Veterinary Science;2022-03-31

5. Sarcomas—A barren immunological wasteland or field of opportunity for immunotherapy?;Veterinary and Comparative Oncology;2020-04-27